Introduction
Peripartum cardiomyopathy (PPCM) is a major cause of pregnancyinduced heart failure and is associated with high morbidity and mortality.
1 -5 The pathophysiology still remains unclear, with multiple factors likely contributing to and driving progression.
One of the most frequently asked questions by patients or treating physicians concerns the health risk of subsequent pregnancies (SSPs). The literature is scarce but clearly indicates that SSPs in may face a relapse. 6 In addition, the review points out that PPCM patients entering SSP with unrecovered LV function have an almost 50% risk of LV deterioration during the SSP. 6 The potential fatal outcome after SSP not only affects the patient herself but will have also a strong social impact on the newborn and any other previously born living children who are dependent on their mother's care. Therefore, management of PPCM patients must involve counselling on risks of additional pregnancies and in this regard also on the appropriate use of contraceptive agents. 10 To date, the management of SSP in PPCM patients is only briefly addressed in current guidelines on pregnancy-related heart diseases.
11 Therefore, data must be collected on optimal management of SSP if a PPCM patient becomes pregnant again, whether planned or accidentally.
Our previous research suggested that the nursing hormone prolactin, which is highly elevated during delivery, and periodically in nursing mothers, is a key player in the pathophysiology of PPCM. We showed that additional factors such as oxidative stress promote the cleavage of prolactin in an antiangiogenic 16 kDa prolactin fragment that is causally involved in PPCM. 12 Furthermore, experimental studies in mice and first clinical pilot studies suggest a beneficial effect of the prolactin blocker bromocriptine (BR) to heal acute PPCM or prevent relapse after SSP.
12,13
In order to evaluate the influence of management and drug treatment on the outcome of SSP in PPCM, we analysed SSPs in 34 PPCM patients collected in South Africa, Germany, and Scotland, who were diagnosed according to the revised definition of the Heart Failure Association of the European Society of Cardiology (ESC). 5 We could confirm the higher risk for persisting heart failure or death in PPCM patients entering SSP with LV function that was not fully recovered and observed a potential beneficial effect of standard therapy for heart failure [STHF; beta-blocker and in most patients also angiotensin-converting enzyme (ACE)-inhibitors/ angiotensin receptor blocker (ARB)] combined with BR started immediately after delivery to prevent a relapse after SSP.
Methods

Data collection
Our local Ethics Committees approved this study. Subsequent pregnancies in 34 patients with clearly diagnosed index PPCM were treated and/or managed either at university hospitals, in tertiary hospitals, or by cardiologists in private practice in South Africa, Germany, or Scotland, between 2005 and 2015. All 34 PPCM patients with SSP matched the diagnostic criteria for PPCM at their index PPCM (LVEF ≤45%) and had absence of previously known cardiomyopathy. 5 All patients provided written informed consent. Minimal requirement for enrolment was fulfilling the criteria for the diagnosis of PPCM, 5 including availability of baseline LVEF at the index pregnancy and LVEF after subsequent pregnancy. Unfortunately, not all patients agreed to provide additional clinical data and this is the reason why not all other data sets are complete in this registry. Clinical assessment such as onset of symptoms and signs during first presentation, echocardiographic analyses, diseases in pregnancy and mode of delivery from index PPCM and SSP were obtained from the patient, the referring physician, and by examining the obstetric cards and medical records. index PPCM at the time of diagnosis, before the SSP, during SSP (second or third trimester), after delivery (while still admitted in hospital), and after at least 6-month follow-up (between 6 and 12 months postpartum). Three patients were excluded: one died during pregnancy, one after delivery, and one was lost to follow-up after delivery.
Drug treatment
If STHF was applied, beta-blocker and in most patients ACE-inhibitor or ARB (decided by the treating physician) treatment started immediately after SSP according to the haemodynamic status of the patient, as recommended by the ESC guidelines. 11 Treatment during pregnancy with beta-blockers was according to the ESC guidelines for pregnant patients with cardiomyopathies. 11 Bromocriptine treatment was administered according to the protocol published in our pilot study 13 to efficiently suppress prolactin by 2.5 mg to 5 mg daily for at least 4 weeks, in addition to STHF. Bromocriptine treatment was also started immediately after delivery. Patients who did not underwent this treatment protocol but received STHF, according to the guidelines, 11 were defined as STHF group.
Analysis of outcome
Patients were classified with regard to recovery according to the 2016 ESC guidelines defining preserved LV function as LVEF >49%. 14 Accordingly, patients were defined as entering SSP with fully recovered function if LVEF was ≥50% and persistently reduced LV function if LVEF was <50% either measured before SSP or assessed within the first trimester of the SSP. As for the recovery state at follow-up of SSP, patients who showed an LVEF ≥50% were classified as fully recovered from PPCM and patients with LVEF <50% or those who died during SSP or after SSP were classified as not recovered or relapse of PPCM after SSP. LVEF after delivery was always measured within the first week after delivery when patients had already obtained medication.
Statistical analysis
Database management and statistical analyses were performed with SAS software, version 9.2 statistical program (SAS, Institute Inc., Cary, NC, USA). Continuous data were expressed as mean ± SD or median and range. Comparison of means and proportions between subgroups at baseline were performed by independent t-test and chi-square statistics, or Fisher exact test, respectively, where necessary. Wilcoxon rank-sum test was used if data were not normally distributed. Significance was assumed at a two-sided value of P < 0.05.
Results
Age, gravidity, parity and cardiac function at index peripartum cardiomyopathy and at delivery of subsequent pregnancy
The 34 PPCM patients presented with a mean LVEF of 31 ± 7% at index pregnancy and a mean LVEF of 50 ± 10% before SSP. The median parity at SSP in all 34 patients was 3 (range 1-6). In four patients, pregnancy ended prematurely (one patient died in pregnancy and three had an abortion in the first trimester) and 30 patients had full-term pregnancies. In order to analyse the outcome after SSP we followed patients for at least 6 months (6-68 months). Follow-up data after delivery were available for 32 patients as one patient had died during SSP and one patient was lost to follow-up. The mean follow-up LVEF was 47 ± 13%. Recovered PPCM (LVEF ≥50%) at follow-up was observed in 43% (15/32) of patients, while adverse outcome (death, n = 3) or persistently reduced LVEF (<50%) was present in 57% (17/32). The overall mortality rate in this collective of PPCM patients with SSP was 12% (4/34).
Left ventricular function at index peripartum cardiomyopathy, pregnancy complications and outcome, and mode of delivery of subsequent pregnancies
In the 32 patients with follow-up data, those with recovery at follow-up displayed a similar LVEF at index PPCM to that of patients with no recovery after SSP (recovered SSP, LVEF at index PPCM: 32 ± 5%, n = 15 vs. unrecovered SSP; index PPCM: 31 ± 6, n = 17, P = 0.78). In addition, neither age, gravity, parity, pregnancy outcome (abortion, twin pregnancy), pregnancy-associated hypertension, smoking, or mode of delivery were different between patients with or without recovery after SSP.
Clinical presentation and outcome of subsequent pregnancies in patients who entered subsequent pregnancies with recovered vs. not recovered left ventricular function
Previous reports suggested that recovery of LV function before SSP is associated with a better outcome of SSP. 7 At follow-up (at least 6 months after delivery), the proportion of patients with stable full recovery (LVEF ≥50%) tended to be higher in patients entering SSP with fully recovered LV function compared with those entering SSP with persistently reduced LVEF. However, the difference was not significant ( Table 1) .
Outcome of patients receiving standard therapy for heart failure alone or with addition of bromocriptine immediately after delivery of subsequent pregnancy
Medical records were available for 30 of the 34 patients. Of these, 21 patients were given beta-blocker therapy whereas eight patients did not receive beta-blockers during pregnancy. After delivery, all 30 patients received beta-blocker therapy and 25 received ACE-inhibitors/ARB, defined as STHF. Of these, 21 patients received STHF and BR (which was started immediately after delivery) and nine received STHF alone. No significant differences were observed between the two groups with regard to gravida, parity, African race, LVEF at index PPCM, or LVEF before SSP ( Table 2 ). In addition, a comparable proportion of patients in both groups entered SSP with unrecovered cardiac function (LVEF <50%) and received beta-blockers (100%) and ACE-inhibitors/ARB (17/21 in the STHF + BR group and 8/9 in the STHF group, as decided by the treating physician). The STHF + BR group displayed a trend to older age at SSP. Moreover, they showed a trend to better LVEF in the first week after delivery, with significantly better LVEF at follow-up of SSP compared with the group treated with STHF alone ( Table 2 ). The time-course of individual LVEF before SSP, after delivery, and at follow-up of SSP in patients treated with STHF alone or with STHF + BR is depicted in Figure 1 Table 2 ). In addition, no patient in the STHF + BR group died during follow-up of SSP, while two patients died in the STHF group.
Discussion
An important component of the care for women with PPCM is the discussion of the risk of a relapse during or after a SSP. Previous studies suggest that some degree of cardiac dysfunction recurs in most PPCM patients in the postpartum phase of an SSP, with a higher risk for adverse outcome when LV structure and function had not completely recovered before SSP.
2,7,9
Here we report data from PPCM patients with SSPs followed prospectively at three university hospitals in South Africa, Germany, and Scotland. We observed that despite the high risk of a relapse of heart failure, half of the patients presenting with an SSP in our study were entering it with LV function not fully recovered. Indeed, these patients had a substantially higher risk of a fatal outcome of SSP as all patients who died during or after SSP in the present study had entered the SSP with a LVEF that was not fully recovered. Moreover, persistently reduced LV function before entering SSP was associated with lower cardiac function in the early phase after SSP delivery and a lower chance for full recovery during follow-up. However, even in patients entering SSP with fully recovered cardiac function, stable full recovery at follow-up of SSP was only observed in 56%, showing that PPCM patients with fully recovered LV function also have a substantial risk for relapse in SSP.
It has been reported that women of African ethnicity may have a poorer outcome of PPCM. 15 We found that the prevalence of patients entering SSP with persistently reduced LVEF was higher among patients of African ethnicity. In addition, three out of the four patients who died during or after SSP were African women, suggesting that they may indeed have a higher risk of a fatal outcome of SSP. In contrast, clinical conditions such as age, gravida, para, twin pregnancy, hypertension in pregnancy, and/or smoking did not differ between patients with fully recovered cardiac function after SSP and those who remained in heart failure or died, suggesting that these factors do not have a substantial impact on SSP outcome.
Guidelines on the management of cardiovascular disease in pregnancy 11 suggest that patients with existing or previous cardiomyopathies may receive beta-blockers during pregnancy. In the present study, the majority of patients were treated with beta-blocker during SSP. However, whether this was beneficial or not could not be evaluated because the number of patients analysed was too small to draw any conclusion. Future observations, for example deriving from the international PPCM registry of the EURObservational Research Programme (http://www.escardio.org/Guidelines-&-Education/Trials-andRegistries/Observational-registries-programme/PeriPartumCardioMyopathy-PPCM-Registry), will provide more data on the benefit of medication during SSP.
16
We hypothesized that immediate treatment after delivery may have an influence on recovery after SSP. In line with this, our previous research suggested that a cleaved 16 kDa fragment of the nursing hormone prolactin is a key player in the pathophysiology of PPCM and that blocking whole prolactin with BR can prevent onset of the disease in mice, and may prevent PPCM or promote healing from PPCM in humans. cardiac function at follow-up in patients receiving STHF + BR compared with patients receiving STHF alone. Moreover, no patient in the STHF + BR group died, while two patients in the STHF group died during follow-up, suggesting that this combination therapy may indeed prevent relapse of PPCM and has beneficial effects when started as early as possible after delivery. However, the number of patients was small and additional information is required (for example from the EURObservational Research Programme) to achieve more conclusive data.
Conclusion
All PPCM patients should be counselled regarding the risk of worsening heart failure, and even death in SSP, as the risk is substantial even in patients with recovered LV function before SSP. Importantly, the risk for fatal outcome of SSP with regard to persisting heart failure or death is particularly high if patients enter SSP with LVEF that is not fully recovered. Moreover, African ethnicity may further increase the risk of an adverse outcome of an SSP after PPCM. In case of SSP in a PPCM patient, management by an interdisciplinary team of cardiologists, obstetricians, anaesthetists, and neonatologists is recommended and all patients need to be monitored carefully for at least 6 months postpartum, and perhaps for lifelong. In addition, despite some limitations such as small cohort size and non-randomized design, our data suggest that progression of heart failure and fatal outcome of SSP may be attenuated or prevented if a STHF + BR therapy is initiated immediately after delivery in SSP. However, larger studies and, in particular, long-term outcome data are urgently needed.
